STOCKHOLM, Feb. 5, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025.

Fourth Quarter 2025

Total revenue increased 5 per cent, 16 per cent at CER¹, to SEK 7,821 M (7,436)
Haematology revenue increased 25 per cent at CER to SEK 5,143 M (4,487), mainly driven by strong sales of Altuvoct of SEK 1,023 M (302) and of Doptelet of SEK 1,508 M (1,147), somewhat offset by lower sales of Vonjo of SEK 327 M (416)
Immunology revenue increased 2 per cent at CER to SEK 2,337 M (2,564), driven by strong sales of Gamifant of SEK 763 M (512) and Kineret sales of SEK 741 M (777), offset by lower Beyfortus royalty of SEK 849 M (1,207)
Revenue from the strategic portfolio¹ grew by 37 per cent at CER to SEK 5,059 M (4,099)
The adjusted EBITA margin^1,2 was 41 per cent (34), excluding IAC² of SEK -142 M. EBITA¹ was SEK 3,075 M (2,572), corresponding to a margin of 39 per cent (35). EBIT was SEK 2,358 M (1,662)
Earnings per share (EPS) before dilution was SEK 5.39 (4.07) and EPS after dilution was SEK 5.34 (4.02). Adjusted EPS before dilution¹ was SEK 5.70 (4.03) and adjusted EPS after dilution¹ was SEK 5.65 (3.98)
Cash flow from operating activities was SEK 2,981 M (1,797)

Full Year 2025

Total revenue increased 8 per cent, 15 per cent at CER to SEK 28,238 M (26,027). Haematology grew 23 per cent at CER and Immunology grew 1 per cent at CER
The adjusted EBITA margin^1,2 was 40 per cent (36), excluding IAC²
The board of directors proposes that no dividend is paid for the 2025 financial year

Outlook 2026

Revenue is anticipated to grow at low double-digit percentage at CER
The adjusted EBITA margin is anticipated to be in the mid 30s percentage of revenue

1. Alternative Performance Measures (APMs).
2. Items affecting comparability (IAC).

Investors, analysts, and the media are invited to a conference call on the same day at 13:00 CET, 12:00 GMT, and 07:00 EST. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please find the details here.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 05 February 2026 at 8:00 CET.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q4-and-fy-2025-report--closing-the-year-with-significant-growth-and-strategic-progress,c4302724

The following files are available for download:


 
 https://mb.cision.com/Main/14266/4302724/3917798.pdf Q4 and FY 2025
                                                          report

View original content:https://www.prnewswire.co.uk/news-releases/sobi-q4-and-fy-2025-report-closing-the-year-with-significant-growth-and-strategic-progress-302679916.html

Tags

More Like This

Sobi publishes Q4 2024 report: A solid ending to a strong year

Sobi publishes Q1 2025 report: Portfolio continues to deliver

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

Sobi Q3 2025 report: Accelerated growth and portfolio momentum

Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Sobi Q3 2024 report: Strong growth and significant pipeline momentum